ZACCARELLI, Monica
 Distribuzione geografica
Continente #
NA - Nord America 738
EU - Europa 303
AS - Asia 83
SA - Sud America 3
OC - Oceania 1
Totale 1.128
Nazione #
US - Stati Uniti d'America 737
SE - Svezia 118
GB - Regno Unito 54
IT - Italia 42
HK - Hong Kong 39
FI - Finlandia 29
DE - Germania 23
CN - Cina 20
BG - Bulgaria 12
MY - Malesia 11
RU - Federazione Russa 11
SI - Slovenia 6
ID - Indonesia 4
VN - Vietnam 4
BR - Brasile 2
FR - Francia 2
IN - India 2
PL - Polonia 2
SG - Singapore 2
AU - Australia 1
BE - Belgio 1
CA - Canada 1
CL - Cile 1
KR - Corea 1
MK - Macedonia 1
NL - Olanda 1
UA - Ucraina 1
Totale 1.128
Città #
Chandler 136
Fairfield 107
Ashburn 84
Nyköping 83
Woodbridge 51
Southend 42
Houston 41
Hong Kong 39
Seattle 31
Helsinki 29
Cambridge 28
Wilmington 25
Fremont 15
Modena 15
Princeton 14
Ann Arbor 12
Sofia 12
San Diego 11
Shanghai 10
New York 9
Bremen 7
Genoa 6
London 5
Dong Ket 4
Jacksonville 4
Jakarta 4
Beijing 3
Hanover 3
Bomporto 2
Chicago 2
Formia 2
Frankfurt am Main 2
Leawood 2
Milan 2
Munich 2
Norwalk 2
Scottsdale 2
Singapore 2
Stockholm 2
Velikiy Novgorod 2
Warsaw 2
Amsterdam 1
Andover 1
Berlin 1
Brussels 1
Cheboksary 1
Chelyabinsk 1
Dallas 1
Edinburgh 1
Hangzhou 1
Hounslow 1
Incheon 1
Islington 1
Kilburn 1
Manchester 1
Miami 1
New Orleans 1
Ossona 1
Phoenix 1
Piacenza 1
Poggiomarino 1
Prescot 1
Pune 1
Redwood City 1
Rome 1
Salavat 1
San Mateo 1
Skopje 1
Sydney 1
São Paulo 1
Toronto 1
Volga 1
Wuhan 1
Yaroslavl 1
Totale 889
Nome #
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 116
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 102
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens 99
Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe 98
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study 95
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 91
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus 85
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort 81
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA 80
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 74
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 70
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals 55
Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) study 54
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 46
Totale 1.146
Categoria #
all - tutte 7.557
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.557


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021349 0 0 0 0 117 100 18 36 23 22 27 6
2021/2022245 3 19 16 4 17 14 12 6 40 11 60 43
2022/2023392 65 65 25 31 57 27 14 30 28 2 20 28
2023/2024160 7 15 10 34 41 8 16 14 1 2 3 9
Totale 1.146